Sivelestat shows significant potential to improve clinical outcomes in patients suffering from respiratory or cardiac pathologies

Sepsis is a serious medical condition associated with high morbidity and mortality rates. It often leads to complications such as acute respiratory distress syndrome (ARDS) and sepsis-induced cardiomyopathy (SCM).

Between January 2019 and December 2021, a randomised controlled trial was conducted on patients admitted to the Intensive Care Unit (ICU) of Wuhan Union Hospital, diagnosed with ARDS and SCM. Patients were divided into two groups: a sivelestat-treated group and a control group. Sivelestat was administered intravenously at a dose of 0.2 mg/kg/hour from the time of diagnosis and continued until discharge from the ICU or for up to 14 days.